New lupus drug combo enters first human safety trial
NCT ID NCT07512947
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called YKST02, given alone or with another drug YK012, in 30 people with active or hard-to-treat lupus. The main goal is to see if the drugs are safe and tolerable. Participants will receive intravenous infusions and be monitored for about 49 weeks, with blood samples taken to study how the drugs work in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YKST02 (a drug) given alone or with YK012 (another drug)
- What this could lead to
- If this early trial shows the drugs are safe and seem to work, it could point toward a new treatment option for people with active lupus that hasn't responded to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 30 people. It is designed mainly to check safety, not to prove the drugs work. The drugs may not be effective or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEM LUPUS ERYTHEMATOSUS(SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test for lupus kidney damage?
- Can reprogrammed immune cells silence lupus? a small trial aims to find out.
- Lupus brain fog? a simple exercise program might help clear it
- Step by step: walking program shows promise for lupus fatigue
- Experimental CAR-T shot targets three tough autoimmune diseases
- Experimental cell therapy takes on lupus in early trial